Free Trial

Xenetic Biosciences (XBIO) Stock Forecast & Price Target

Xenetic Biosciences logo
$3.66 +0.01 (+0.27%)
(As of 11/14/2024 ET)

Xenetic Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
0

Based on 1 Wall Street analysts who have issued ratings for Xenetic Biosciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 1 analysts, 1 has given a hold rating for XBIO.

Consensus Price Target

N/A

Get the Latest News and Ratings for XBIO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Xenetic Biosciences and its competitors.

Sign Up

XBIO Analyst Ratings Over Time

TypeCurrent Forecast
11/15/23 to 11/14/24
1 Month Ago
10/16/23 to 10/15/24
3 Months Ago
8/17/23 to 8/16/24
1 Year Ago
11/15/22 to 11/15/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
N/A
0 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
N/A
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
N/A
0 Sell rating(s)
Consensus Price TargetN/AN/AN/A$40.00
Forecasted UpsideN/AN/AN/A1,190.32% Upside
Consensus Rating
Hold
Hold
N/A
Hold

XBIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

XBIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Xenetic Biosciences Stock vs. The Competition

TypeXenetic BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted UpsideN/A19,889.00% Upside8.58% Upside
News Sentiment Rating
Neutral News

See Recent XBIO News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/20/2024HC Wainwright
2 of 5 stars
 Reiterated RatingNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:49 PM ET.


XBIO Forecast - Frequently Asked Questions

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There is currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares.

According to analysts, Xenetic Biosciences's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Xenetic Biosciences has been rated by research analysts at HC Wainwright in the past 90 days.

Analysts like Xenetic Biosciences less than other "medical" companies. The consensus rating for Xenetic Biosciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how XBIO compares to other companies.


This page (NASDAQ:XBIO) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners